There are 2789 resources available
137P - Trial comparing the safety, efficacy and immunogenicity of trastuzumab biosimilar candidate (TX05) with originator trastuzumab in HER2+ early breast cancer
Presenter: Peter Krivorotko
Session: ePoster Display
139P - HER2+/HR+ breast cancer patients at high risk of relapse derive benefit from extended adjuvant treatment with neratinib: An exploratory analysis from ExteNET study
Presenter: Francesco Cognetti
Session: ePoster Display
140P - Benefit of adjuvant chemotherapy in luminal A-like early breast cancer in women aged 40 years or younger: Results of a national multi-institutional study
Presenter: Ondine Dufour
Session: ePoster Display
141P - Gene-expression pathways and dynamics during neoadjuvant chemo-free therapy predict pathologic complete response in ER+/HER2+ breast cancer (BC)
Presenter: Matteo Dugo
Session: ePoster Display
143P - The impact of de-escalation of adjuvant systemic therapy on the outcome of women with early ER+/HER2+ breast cancer
Presenter: Valentina Jeric Horvat
Session: ePoster Display
144P - A personalised sequencing approach for liquid biopsy-based detection of recurrent disease in early-stage breast cancer
Presenter: Wolfgang Janni
Session: ePoster Display
145P - High-risk breast cancer patients with RAD51-low tumors are characterized by good prognosis
Presenter: Benedetta Pellegrino
Session: ePoster Display
146P - Prognostic impact of HER2-low expression according to the oncotype Dx recurrence score in hormone receptor-positive early breast cancer
Presenter: Raz Mutai
Session: ePoster Display